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ABSTRACT While there is evidence for variations in prevalence rates of childhood wheeze and asthma between
countries, longitudinal, individual-level data are needed to understand these differences. The aim of this study was
to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe.
We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts in eight
countries, representing 26663 children, to calculate prevalence rates of wheeze and asthma by child age
and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze
and parent-reported doctor-diagnosed asthma, and covariates maternal education, parental smoking, pets,
parental asthma, doctor-diagnosed allergic rhinitis, doctor-diagnosed eczema and wheeze severity.
At age 4 years, asthma prevalence varied from 1.72% in Germany to 13.48% in England and the
prevalence of wheeze varied from 9.82% in Greece to 55.37% in Spain. Adjusted estimates of the
proportion of 4-year-old children with wheeze diagnosed with asthma remained highest in England
(38.14%, 95% CI 31.38–44.90%) and lowest in Spain (15.94%, 95% CI 6.16–25.71%).
The large differences in prevalence rates of asthma, wheeze and wheeze with asthma at age 4 years
between European cohorts may indicate that childhood asthma is more readily diagnosed in some
countries while going unrecognised elsewhere.
@ERSpublications
Large variations in childhood wheeze across Europe do not match large variations in diagnosed
childhood asthma http://ow.ly/eJQk30aPInr
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Introduction
Global burden of disease
In the International Study of Asthma and Allergies in Childhood (ISAAC), the global prevalence of
wheeze was estimated to be 11.6% for 6–7-year-old children and 13.7% for 13–14-year-old children for the
period around 2001–2003 [1]. Wheeze is particularly prevalent in English-speaking and Western countries
[2]. Far less data are available on international prevalence rates of doctor-diagnosed asthma in children.
The ISAAC study estimated the global prevalence of parent-reported doctor-diagnosed asthma among
6–7-year-old children to be 10.8%, with lower rates in Northern and Eastern Europe (4.5%), and the
highest rates in North America (20.0%) and Oceania (29.2%). This pattern was repeated in 13–14-year-old
children, with figures suggesting a small increase with age of ∼2% in most countries except for Western
Europe (9.1% among 6–7-year-olds to 16.3% among 13–14-year-olds) [1].
Wheeze versus doctor-diagnosed asthma
Self-reported wheeze is often used as an indicator of asthma [1]. While wheeze and asthma frequently go
hand-in-hand, wheeze is not a sufficient, nor a necessary symptom, for the diagnosis of asthma. Partly due
to the highly variable expression of asthma, there is no uniform set of diagnostic criteria [3]. SPYCHER et al.
[4] showed that only 2.9% of all children in the general population present with the combination of
wheeze, atopy and bronchial hyperresponsiveness described as typical for asthma. In another study, 25.8%
of young adults with asthma never experienced childhood wheeze and of the children with wheeze, 51.8%
did not develop asthma [5]. If differences between prevalence rates of wheeze and asthma vary
internationally, using wheeze as a proxy for asthma is problematic.
Gaps in the evidence
Despite evidence of varying prevalence rates, no international comparisons of wheeze in combination with
doctor-diagnosed asthma by child age are available. The ISAAC survey only measures self-reported wheeze
and asthma in two age groups consisting of different samples [1]. Studying these variations between
countries could lead to a greater understanding of modifiable factors involved, e.g. relating to the
environment or the diagnostic process. The MeDALL (Mechanisms of the Development of ALLergy)
partnership provides individual-level, longitudinal data with harmonised measures of wheeze and
doctor-diagnosed asthma across cohorts [6]. We aimed to examine variations in the prevalence of
childhood asthma, wheeze and wheeze with asthma by child age in Europe.
Methods
We analysed cross-sectional differences in childhood asthma and wheeze by child age and wheeze with
asthma at age 4 years in datasets from European cohorts with harmonised variables on asthma and
wheeze. Data were requested from 13 MeDALL cohort studies [6]. Table 1 provides an overview of the 10
included cohorts, representing eight countries and a total sample of 26663 children. More information
about the cohorts can be found in the ENRIECO database (www.enrieco.dk).
Measures
The MeDALL partnership has developed harmonised variables, including harmonised definitions of
asthma and wheeze [7]. “Ever asthma” is defined by the question “Has your child ever been diagnosed by
a doctor as having asthma?” and “ever wheeze” is captured by the question “Has your child ever had
wheezing or whistling in the chest?” For BAMSE, LISAplus and GINIplus cohorts, only wheeze and
doctor diagnosis of asthma in the past 12 months were available in the follow-ups analysed, and composite
measures based on annual reports of wheeze and/or asthma were created where possible (supplementary
table S1). A third outcome measure was constructed to capture the proportion of children whose parents
reported wheeze at least once from birth until age 4 years and who were reported to be diagnosed with
asthma by age 4 years.
Key covariates included maternal education (low/medium/high, cohort specific), parental smoking up to
child age 4 years, pets in the household up to child age 4 years (dog and/or cat and/or other pets, cohort
specific), parental ever asthma, ever doctor-diagnosed allergic rhinitis and ever doctor-diagnosed eczema.
This article has supplementary material available from openres.ersjournals.com
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TABLE 1 Overview of included MeDALL birth cohorts
Cohort Country Period of
recruitment
Sample
size n#
Inclusion
criteria¶
Exclusion criteria Setting
BAMSE (The Stockholm
Children Allergy and
Environmental
Prospective Birth Cohort
Study)
Sweden 1994–1996 4089 Birth in the
selected areas
Disabled infants, plan to
move, language barrier
Three areas of
Stockholm (urban
and suburban)
BiB (Born in Bradford) England 2007–2010 1716 Birth at
reference
hospital
Plan to move before birth Bradford (largely
urban)
GINIplus (German Infant
Nutritional Intervention
study plus influence of
pollution and genetics on
allergy development)
Germany 1995–1998 5991 Healthy
full-term
newborns of
German descent
Severe illness newborn,
pre-term birth, low
birthweight, language barrier,
maternal history of
immune-related disease,
long-term medication or
drug/alcohol abuse
Munich (mostly
urban), Wesel
(mostly rural)
INMA (Childhood and
Environment)
Menorca Spain 1997–1998 482 Birth at
reference
hospital
Language barrier, assisted
reproduction, mother
<16 years, multiple births
Menorca (mostly
urban)
Valencia Spain 2003–2005 855 Birth at
reference
hospital
Language barrier, assisted
reproduction, mother
<16 years, multiple births
Valencia (mostly
urban)
Sabadell Spain 2004–2007 772 Birth at
reference
hospital
Language barrier, assisted
reproduction, mother
<16 years, multiple births
Sabadell (mostly
urban)
Gipuzkoa Spain 2006–2008 406 Birth at
reference
hospital
Language barrier, assisted
reproduction, mother
<16 years, multiple births
Gipuzkoa (mostly
urban)
LISAplus (Influence of
lifestyle factors on the
development of the
immune system and
allergies in East and West
Germany plus the
influence of traffic
emissions and genetics)
Germany 1997–1998 3094 Healthy
full-term
newborns of
German descent
Severe illness newborn,
pre-term birth, low
birthweight, language barrier,
maternal history of
immune-related disease,
long-term medication or
drug/alcohol abuse
Munich (mostly
urban), Wesel
(mostly rural),
Leipzig (mostly
urban), Bad Honneff
(mostly rural)
MAS (Multicentre Allergy
Study)
Germany 1990 1314 Birth at
reference
hospitals
Language barrier,
complications at birth,
pre-term birth, low
birthweight
Berlin, Düsseldorf,
Freiburg, Mainz,
Munich (urban)
PARIS (Pollution and
Asthma Risk: an Infant
Study)
France 2003–2006 1549 Healthy
newborns
Pre-term, low birthweight,
intensive care treatment,
language barrier
Paris and three
suburbs (urban)
PIAMA (Prevention and
Incidence of Asthma and
Mite Allergy)
The
Netherlands
1996–1997 3963 Usable
screening
questionnaire
Mix of rural, urban,
suburban
RHEA (Mother Child Cohort
in Crete)
Greece 2007–2008 1336 Birth at
reference
hospitals
Mother ⩽16 years, language
barrier
Heraklion (island,
mix of urban,
suburban and rural)
ROBBIC (Rome and Bologna
Birth Italian Cohorts)
Co.N.ER (Bologna birth
cohort)
Italy 2004–2005 434 Mother Italian
citizen, birth at
reference
hospital
Language barrier, newborn
moved hospital, mother
⩽18 years
Bologna (urban)
GASPII (Gene and
Environment: Prospective
Study on Infancy in Italy)
Italy 2003–2004 694 Mother Italian
resident
Language barrier, newborn
moved hospital, mother
⩽17 years
Rome (urban)
#: number of pregnant women or mothers as used in this study; ¶: inclusion based on area of residence specified in last column.
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Severity of wheeze was considered a potential explanatory variable in the relationship between cohort and
percentage of children with wheeze diagnosed with asthma. However, as it was only available in five
cohorts, it was used in additional analyses only. The measure was constructed from the question “How
many attacks of wheezing has your child had in the last 12 months?” and coded low (0 times), medium or
high severity (coding varied by cohort).
Statistical analysis
Prevalence rates of wheeze and asthma were calculated up to age 8 years, because four cohorts had no data
from later time points (ROBBIC, RHEA, BiB and PARIS) and for many other cohorts a high loss to
follow-up affected the reliability of the data (supplementary table S1).
Data for subcohorts in INMA and ROBBIC were pooled, although data availability differed across
subcohorts for different time points (table 1). Cross-sectional logistic regression analyses were performed
separately for outcomes asthma at age 4 years, wheeze at age 4 years and wheeze with diagnosed asthma at
age 4 years. Unadjusted prevalence rates are presented by child age for all cohorts, and unadjusted and
adjusted prevalence rates are presented for all cohorts at age 4 years, as this was the follow-up age with most
data available across cohorts. Prevalence rates at age 4 years could not be calculated for the ROBBIC, MAS,
GINIplus and LISAplus cohorts, because these studies did not measure the relevant outcomes at age 4 years.
Results
Characteristics of the cohort participants by cohort are described in supplementary table S2. Unadjusted
prevalence rates and output from regression analyses are reported in supplementary table S3.
Prevalence rates of asthma and wheeze by child age
In all cohorts with longitudinal data, figure 1 suggests a trend for prevalence rates of asthma to increase
with child age. Differences between prevalence rates at the first and last time point are statistically
significant for each cohort (supplementary table S3). However, there were large differences between
cohorts across the entire age range. Reported ever wheeze did not consistently increase with child age
(figure 2).
Ever asthma at age 4 years
At age 4 years, for which eight cohorts provided data, unadjusted prevalence rates of ever asthma varied
from 1.72% (95% CI 1.22–2.35%) in Germany (LISAplus) to 13.48% (95% CI 11.88–15.20%) in England
(BiB) (figure 3).
Asthma at age 4 years was not associated with the presence of pets in the home (OR 1.02, 95% CI
0.88–1.18), but was associated with medium (OR 0.84, 95% CI 0.70–1.00) and high (OR 0.74, 95% CI
0.62–0.88) versus low maternal education, parental smoking (OR 1.31, 95% CI 1.10–1.57), parental asthma
(OR 2.38, 95% CI 2.07–2.73), doctor-diagnosed allergic rhinitis (OR 4.12, 95% CI 3.23–5.25) and
doctor-diagnosed eczema (OR 2.21, 95% CI 1.93–2.53).
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FIGURE 1 Prevalence rates of ever asthma by cohort (table 1) and child age.
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After adjusting for these covariates, prevalence rates shown in figure 3 indicate that large and consistent
differences in diagnosed asthma at age 4 years remain. Again, the highest prevalence rates of asthma are
found in England (BiB), Sweden (BAMSE) and France (PARIS), while Germany (GINIplus and LISAplus)
and Spain (INMA) have the lowest rates.
Ever wheeze at age 4 years
There was a wide variation in prevalence rates of ever wheeze at age 4 years. However, cohorts with the
highest average prevalence of asthma at age 4 years (figure 3) do not have the highest average prevalence
of wheeze at age 4 years (figure 4). Unadjusted prevalence rates of wheeze at age 4 years for six cohorts
with available data varied from 9.82% (95% CI 7.95–11.96%) in Greece (RHEA) to 55.37% (95% CI
52.21–58.51%) in Spain (INMA).
Wheeze at age 4 years was not associated with maternal education (OR 1.03, 95% CI 0.93–1.15 and OR
1.01, 95% CI 0.91–1.12 for low and medium versus high education, respectively) nor with pets in the
home (OR 1.05, 95% CI 0.97–1.14), but was associated with parental smoking (OR 1.42, 95% CI
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FIGURE 3 Unadjusted and adjusted prevalence rates of ever asthma at age 4 years by cohort (table 1).
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FIGURE 2 Prevalence rates of ever wheeze by cohort (table 1) and child age.
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1.28–1.58), parental asthma (OR 1.71, 95% CI 1.57–1.87), doctor-diagnosed allergic rhinitis (OR 2.24, 95%
CI 1.84–2.71) and doctor-diagnosed eczema (OR 1.52, 95% CI 1.40–1.65). Adjusted prevalence rates of
wheeze remain highest in Spain (INMA), and lowest in France (PARIS) and Greece (RHEA) (figure 4).
Children with ever wheeze diagnosed with asthma by age 4 years
The proportion of children with ever wheeze who were diagnosed with asthma by age 4 years ranged from
15.94% (95% CI 8.24–26.74%) in Spain (INMA) to 39.53% (95% CI 35.07–44.12%) in England (BiB)
(figure 5).
Wheeze with diagnosed asthma compared with wheeze without diagnosed asthma at age 4 years was not
associated with low- versus medium-level maternal education (OR 0.83, 95% CI 0.65–1.05), but children
with wheeze were less likely to be diagnosed with asthma if their mother had a low versus high level of
education (OR 0.71, 95% CI 0.56–0.90). There was no association with parental smoking (OR 1.05, 95%
CI 0.83–1.34) or pets (OR 1.01, 95% CI 0.82–1.24), but wheeze with asthma was more likely in children of
parents with asthma (OR 1.85, 95% CI 1.52–2.24), children diagnosed with allergic rhinitis (OR 2.81, 95%
CI 1.86–4.24) and children diagnosed with eczema (OR 1.68, 95% CI 1.40–2.03).
The probability of children with wheeze being diagnosed with asthma by age 4 years was also increased for
medium versus low (OR 1.90, 95% CI 1.52–2.39) and high versus low wheeze severity (OR 5.65, 95% CI
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FIGURE 5 Prevalence rates of wheeze with diagnosed asthma at age 4 years by cohort (table 1).
FIGURE 4 Unadjusted and adjusted
prevalence rates of ever wheeze at
age 4 years by cohort (table 1).
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4.24–7.54). However, adding wheeze severity to the model did not reduce between-cohort differences
(figure 5). Estimates for children with wheeze diagnosed with asthma in the fully adjusted model were
higher for England (BiB) (49.17%, 95% CI 39.17–59.18%) and France (PARIS) (52.07%, 95% CI
40.79–63.35%) than for Sweden (BAMSE) (27.06%, 95% CI 24.07–30.05%), the Netherlands (PIAMA)
(22.49%, 95% CI 19.37–25.61%) and Spain (INMA) (15.31%, 95% CI 5.58–25.04%).
Discussion
Prevalence rates of childhood asthma and wheeze vary by country, with a seven-fold variation in asthma
across cohorts at age 4 years and persisting differences at older ages. Whereas the prevalence of asthma
generally increases with age, the prevalence of wheeze does not. The highest prevalence rates of asthma were
found among cohorts in England, Sweden and France, and the lowest in Germany and Spain. The highest
rates of wheeze were found in Spain, Italy and Sweden, and the lowest in Germany, France and Greece.
Although we showed strong associations with covariates parental smoking, parental asthma, allergic rhinitis
and eczema, these factors did not explain between-cohort differences in prevalence rates.
Discrepancies between prevalence rates of asthma and wheeze were confirmed by differences between
cohorts in the proportion of children with wheeze diagnosed with asthma by age 4 years. Children with
wheeze were more likely to be diagnosed with asthma if their mother had a higher level of education, if
the child was diagnosed with allergic rhinitis or eczema and if wheeze was more severe. However, even
after adjusting for these covariates, children with wheeze were more likely to be diagnosed with asthma in
England and France than in Sweden, the Netherlands and Spain. We consider a few explanations for these
variations.
Explaining variations between European cohorts
To put our findings in perspective, we compared our results with estimates from international surveys
(supplementary appendix S1 and supplementary figure S1). Although no data on doctor-diagnosed
childhood asthma were available, findings from two surveys among adults suggest findings in line with
ours, with the highest prevalence rates of asthma in the UK, Sweden, France and the Netherlands, and
consistently lower prevalence rates in Germany, Spain, Greece and Italy [8, 9]. Our estimates of wheeze in
Spain and Italy are higher than previously found, but these cohorts are not representative of the general
population (supplementary table S4).
Variations may be attributable to international differences in the diagnosis of childhood asthma or
guideline adherence. The PRACTALL (Practical Allergy) consensus recommendations provide guidance for
diagnosis and treatment of childhood asthma in Europe and North America, and state that suspected
asthma can only be diagnosed through follow-up and a trial of treatment [10]. Current Dutch guidelines
are even more cautious and discourage the diagnosis of asthma for children under the age of 6 years [11].
UK guidelines recommend a trial of treatment or watchful waiting for those under the age of 6 years, but
state that more frequent and/or severe symptoms add certainty to the asthma diagnosis [12]. Swedish
guidelines prioritise lung function and allergy tests even for those under the age of 4 years; in France,
radiographs are recommended as standard practice [13, 14]. Furthermore, there are indications of
underdiagnosis of childhood asthma, e.g. in Italy [15], and evidence of overdiagnosis in the Netherlands
[16]. One study found that asthmatic complaints which often led to an asthma diagnosis for children in
the Netherlands were frequently diagnosed and treated as bronchitis in Germany [17]. These differences in
healthcare may contribute to some of the variation in prevalence rates of asthma and wheeze with
diagnosed asthma found in our study.
Alternatively, limited access to healthcare and differences in the translation and interpretation of “wheeze”
might play a role in various countries. The strength of the relationship between wheeze and asthma may
also vary between countries. A recent study comparing childhood mortality rates found that the mortality
rate for paediatric respiratory disorders in England was 6.6 times that of Sweden, despite the prevalence of
childhood asthma being high in both countries [18].
Implications for research
Future research should aim to explain variations in childhood wheeze and diagnosed asthma in
longitudinal analyses, e.g. in age–period–cohort analyses. This could determine whether rates of asthma in
some countries are rising over time, rather than with age alone. We also suggest that, in addition to
environmental factors such as air pollution and climate, international variations in diagnoses, access to
healthcare and quality of care deserve consideration.
A second implication for research concerns the findings that, while the prevalence of childhood asthma
increased with child age, wheeze did not. Wheeze is not a reliable indicator of asthma at an early age when
many young children are yet to be diagnosed. The levelling in the prevalence of ever wheeze with
https://doi.org/10.1183/23120541.00150-2016 7
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increasing child age suggests that these estimates are affected by recall bias. Parents may not remember
transient wheeze suffered by their children at an early age if it does not progress to asthma. A previous
version of the UK guidelines warned that “Parents often use ‘wheezing’ as a non-specific label …” [12].
Using parent-reported wheeze as an indicator of asthma for young children therefore leads to
overestimates of the prevalence of childhood asthma.
Implications for practice
Consensus recommendations have not yet led to an internationally uniform diagnosis of childhood asthma
[10]. Our results suggest that the likelihood of children with asthma being diagnosed, and subsequently
the quality of care, may vary internationally. We have shown that in many countries children are
diagnosed with asthma at age 4 years or earlier, while it is doubtful whether a diagnosis of childhood
asthma can be made with certainty at such a young age. It will take the joint effort of healthcare
professionals and researchers to ensure the diagnosis of childhood asthma is uniform and accurate.
Limitations
As shown in table 1, cohorts used different inclusion and exclusion criteria, and participants were
recruited from centres not representative of the general population. Limited generalisability is particularly
problematic for cohorts using exclusion criteria related to the risk of asthma, such as mothers who do not
speak the language of the country and infants with complications at birth [19–21]. This, in addition to
variations in time periods of data collection and the limited availability of harmonised covariates at
different follow-ups, means that comparisons of prevalence rates between cohorts and within cohorts over
time should be made with caution. For example, composed outcome variables created for some cohorts
were based on data from multiple time points, leading to overestimation. Despite the availability of data at
multiple time points, our analysis was cross-sectional and measured asthma and wheeze “ever” rather than
“in the last 12 months” due to data limitations. However, we believe our conclusions are strengthened by
taking into account key covariates, by the fact that differences between cohorts persist at different child
ages and that these generally correspond with results from other surveys.
Conclusions
There are differences in prevalence rates of childhood asthma and wheeze across Europe, which vary by
child age. The proportion of children with wheeze who were diagnosed with asthma was higher among
cohorts in England, Sweden and France than in the Netherlands and Spain, even when the higher
proportion of severe wheeze in England and France was adjusted for. This may partly indicate that asthma
is more readily diagnosed in some countries, while going unrecognised in others. Given the burden on
patients and healthcare associated with overdiagnosis as well as underdiagnosis, the discussion on
diagnostic criteria for asthma should be an international one.
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